PROSILICO is a leading and award-winning company in the field of human and animal ADME/PK and DDI-predictions.
With unique and validated in-silico methods (n=142), algorithms and platforms PROSILICO has outperformed lab methods (lower errors and costs, higher productivity, range and quality).
Methods can predict bioavailability, t½, excretion, brainability, and the uptake of effluxed and low-solubility compounds.
A <1.5-fold prediction error is reached for the majority of predicted estimates.
PROSILICO predict directly from molecular structure to in-vivo. Results delivered within a week and always together with certainty/uncertainty-estimates and advice.
Currently, PROSILICO has 18 customers (including one big pharma company, and negotiating with more).